Sinergistički efekti koncentracije serumskog albumina i HDL holesterola na koncentraciju oksidovanog LDL holesterola u serumu gojaznih osoba sa normalnom glikoregulacijom i obolelih od dijabetesa melitusa tipa 2

  • Radoslav Pejin University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia; University Clinical Center of Vojvodina, †Clinic for Endocrinology, Novi Sad, Serbia
  • Andrijana Milankov University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia; University Clinical Center of Vojvodina, Clinic for Endocrinology, Novi Sad, Serbia
  • Tijana Ičin University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia; University Clinical Center of Vojvodina, Clinic for Endocrinology, Novi Sad, Serbia
  • Ivana Bajkin University of Novi Sad, Faculty of Medicine, University Clinical Center of Vojvodina, Clinic for Endocrinology, Diabetes and Metabolic Disorders
  • Jelena Niković University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia; University Clinical Center of Vojvodina, Clinic for Neurology, Novi Sad, Serbia
  • Aleksandar Jovanović University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia; University Clinical Center of Vojvodina, Clinic for Neurology, Novi Sad, Serbia
  • Ilija Tanackov University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia; Faculty of Technical Sciences, Novi Sad, Serbia
DOI: https://doi.org/10.2298/VSP240626038P
Ključne reči: albumini;, dijabetes mellitus, insulin nezavisni;, lipoproteini, hdl holesterol;, lipoproteini, ldl holesterol;, gojaznost;, stres, oksidativni

Sažetak


Uvod/Cilj. Serumski albumin i molekuli high-density lipoprotein (HDL) holesterola imaju višestruke fiziološke funkcije, uključujući antioksidativnu ulogu u neutralisanju štetnih efekata oksidovanog lipoproteina niske gustine (oxidized low-density lipoprotein – oxLDL). Kod gojaznih osoba, molekuli albumina i HDL holesterola nisu u stanju da se adekvatno suprotstave nepovoljnim efektima oxLDL holesterola. Cilj rada bio je da se ispitaju funkcionalni odnosi između oxLDL holesterola, HDL holesterola i albumina u serumu. Metode. Studijom je obuhvaćeno 30 gojaznih osoba sa novodijagnostikovanim dijabetesom melitusom tipa 2 (pre i posle tromesečnog lečenja metforminom), 30 gojaznih osoba sa normalnom tolerancijom glukoze i 30 ispitanika normalne težine (kontrolna grupa). Grupe su bile podudarne po starosti i polu. Rezultati. Utvrđene su kvalitativne i kvantitativne razlike u nivoima HDL holesterola i albumina među grupama. Pokazane su statistički značajne promene u linearnim korelacijama između albumina i oxLDL holesterola među ispitivanim grupama. Takođe, formiranjem sinergističkog uticaja nezavisnih varijabli (HDL holesterola i albumina), izraženih kroz složeni polinom zavisne varijable (oxLDL) kvadratnog tipa, uočene su statistički značajne kvalitativne i kvantitativne promene u maksimalnim vrednostima oxLDL u svim ispitivanim grupama Zaključak. Rezultati našeg istraživanja ukazuju na mogući sinergistički efekat albumina i HDL holesterola u prevenciji oksidativnog oštećenja, kao i na mogućnost promene kvaliteta odnosa tih parametara u odnosu na molekule oxLDL holesterola u uslovima koje karakteriše povećan oksidativni stres.

 

Reference

Belinskaia DA, Voronina PA, Shmurak VI, Jenkins RO, Goncharov NV. Serum albumin in health and disease: es-terase, antioxidant, transporting and signaling properties. Int J Mol Sci 2021; 22(19): 10318.

Feng J, Wang Y, Li W, Zhao Y, Liu Y, Yao X, et al. High levels of oxidized fatty acids in HDL impair the antioxidant func-tion of HDL in patients with diabetes. Front Endocrinol 2022; 13: 993193.

Brites F, Martin M, Guillas I, Kontush A. Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit. BBA Clin 2017; 8: 66–77.

Chaudhary P, Janmeda P, Docea AO, Yeskaliyeva B, Abdul Razis AF, Modu B, et al. Oxidative stress, free radicals and antioxi-dants: potential crosstalk in the pathophysiology of human diseases. Front Chem 2023; 11: 1158198.

Sastre-Oliva T, Corbacho-Alonso N, Rodriguez-Sanchez E, Mercado-García E, Perales-Sanchez I, Hernandez-Fernandez G, et al. Al-bumin redox modifications promote cell calcification reflect-ing the impact of oxidative status on aortic valve disease and atherosclerosis. Antioxidants 2024; 13(1): 108.

Fogelman AM. When good cholesterol goes bad. Nat Med 2004; 10(9): 902–3.

Mahfouz MM, Kummerlow FA. High density lipoprotein can modulate the inhibitory effect of Ox-LDL on prostacyclin generation by rat aorta in vitro. Prostaglandins Other Lipid Mediat 2003; 72(3–4): 91–114.

Bowry VW, Stanley KK, Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci USA 1992; 89(21): 10316–20.

Hoekstra M, Van Eck M. High-density lipoproteins and non-alcoholic fatty liver disease. Atheroscler Plus 2023; 53: 33–41.

Poznyak AV, Sukhorukov VN, Surkova R, Orekhov NA, Orekhov AN. Glycation of LDL: AGEs, impact on lipoprotein func-tion, and involvement in atherosclerosis. Front Cardiovasc Med 2023; 10: 1094188.

Zoanni B, Brioschi M, Mallia A, Gianazza E, Eligini S, Carini M, et al. Novel insights about albumin in cardiovascular diseases: Focus on heart failure. Mass Spectrom Rev 2023; 42(4): 1113–28.

Piarulli F, Banfi C, Brioschi M, Altomare A, Ragazzi E, Cosma C, et al. The burden of impaired serum albumin antioxidant properties and glyco-oxidation in coronary heart disease pa-tients with and without type 2 Diabetes Mellitus. Antioxi-dants (Basel) 2022; 11(8): 1501.

Chadwick AC, Holme RL, Chen Y, Thomas MJ, Sorci-Thomas MG, Silverstein RL, et al. Acrolein impairs the cholesterol transport functions of high density lipoproteins. PLoS One 2015; 10(4): e0123138.

Ito F, Ito T. High-density lipoprotein (HDL) triglyceride and oxidized HDL: New lipid biomarkers of lipoprotein-related atherosclerotic cardiovascular disease. Antioxidants (Ba-sel) 2020; 9(5): 362.

Objavljeno
2025/06/27
Broj časopisa
Vol. 82 Br. 06 (2025): Vojnosanitetski pregled
Rubrika
Originalni članak